CorMedix (CRMD) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Does the MarketBeat Community believe in NAMS or CRMD?

CorMedix received 6 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.43% of users gave NewAmsterdam Pharma an outperform vote while only 78.57% of users gave CorMedix an outperform vote.

Company	Underperform	Outperform
NewAmsterdam Pharma	Outperform Votes 27 96.43%	Underperform Votes 1 3.57%
CorMedix	Outperform Votes 33 78.57%	Underperform Votes 9 21.43%

Do analysts prefer NAMS or CRMD?

NewAmsterdam Pharma presently has a consensus target price of $43.33, suggesting a potential upside of 170.33%. CorMedix has a consensus target price of $14.50, suggesting a potential upside of 92.82%. Given NewAmsterdam Pharma's higher possible upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
CorMedix	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Is NAMS or CRMD more profitable?

NewAmsterdam Pharma's return on equity of 0.00% beat CorMedix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
CorMedix	N/A	-79.21%	-64.68%

Which has better earnings and valuation, NAMS or CRMD?

CorMedix has lower revenue, but higher earnings than NewAmsterdam Pharma. CorMedix is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$45.56M	38.64	-$176.94M	-$2.60	-6.17
CorMedix	$43.47M	11.28	-$46.34M	-$0.33	-22.79

Does the media refer more to NAMS or CRMD?

In the previous week, NewAmsterdam Pharma had 1 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for NewAmsterdam Pharma and 4 mentions for CorMedix. CorMedix's average media sentiment score of 0.69 beat NewAmsterdam Pharma's score of 0.66 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CorMedix	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, NAMS or CRMD?

NewAmsterdam Pharma has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Do institutionals & insiders hold more shares of NAMS or CRMD?

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats CorMedix on 10 of the 17 factors compared between the two stocks.